Menoufia Faculty of Medicine
Shebin El-Kom, Menoufia, 32511, Egypt
Location status: Recruiting
NCT Number: NCT06718426
The aim of the study is to evaluate the Fertitonex effects on semen parameters in clinical varicocele patients.
Interested in participating?
Request Info18 year and older
Male
Interventional
Not applicable
Shebin El-Kom, Menoufia, 32511, Egypt
Location status: Recruiting
Infertility is defined as the inability of a couple to conceive after one year of unprotected, frequent and regular sexual intercourse. Almost 15% of all couples trying to conceive are affected by infertility, and in almost half of these cases male infertility is the sole or a contributing factor. The most common cause is idiopathic oligoasthenoteratozoospermia (OAT) that is defined as follows sperm concentration, the proportion of morphologically normal sperm and the proportion of motile sperm are all lower than the World Health Organization (WHO) reference values.
Despite extensive research, a successful treatment for OAT had not yet been developed. Small amounts of reactive oxygen species (ROS) are produced by spermatozoa in physiological conditions, and various scavengers act to reduce the concentration of these ROS in the seminal plasma. ROS are needed for capacitation, acrosome reaction and ultimately fertilization.
Antioxidants might help maintain the balance between ROS production and clearance and thus could improve sperm quality Additionally, observational studies had found a lower frequency of sperm aneuploidy in men with a higher dietary intake of antioxidants than in those with a lower intake. In semen, antioxidants decrease OS, potentially improving sperm motility and reducing DNA fragmentation.
We aim to evaluate the Fertitonex effects on semen parameters in clinical varicocele patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fertitonex which contains L- carnitine L-tartarate 300 mg, L-arginine 241mg, vitamin B6 1.1 mg, vitamin B12 1.7 mcg, vitamin D3 2 mcg, vitamin E 6.5 mg, vitamin C 60 mg, selenium 28 mcg, zinc 7.5 mg, folic acid 300 mcg and CoQ 10 enzyme 7.5 mg in each capsule. The dose will be one capsule twice daily for 3 months.
placebo oral capsule. the dose is twice daily for 3 months
Time frame: 3 months
Total sperm count will be assessed by Semen analysis done after 3 months of either fertitonex or placebo administration.
Total sperm count will be measured by number of sperms present in the semen sample.
Time frame: 3 months
Sperm motility will be assessed by semen analysis done after 3 months of either fertitonex or placebo administration.
Both total motility will be measured by percentage of motile sperms and progressive motility will be measured by percentage of progressively motile sperms present in the semen sample.
Time frame: 3 months
Sperm morphology will be assessed by semen analysis done after 3 months of either fertitonex or placebo administration.
Sperm morphology will be measured by percentage of normally shaped sperms present in the semen sample.
Contact information is provided by the study sponsor or research team.
Menoufia University
Other
Evaluation of Fertitonex Effects on Semen Parameters in Clinical Varicocele Patient, Placebo Controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07684963
Cardiovascular Diseases, Genital Diseases
View Trial DetailsNCT07665905
Cardiovascular Diseases, Genital Diseases
Ankara, Keçiören, Turkey (Türkiye)
View Trial DetailsNCT04509869
Cardiovascular Diseases, Fertility Issues
Asyut, Assuit, Egypt
View Trial DetailsNCT01463787
Cardiovascular Diseases, Genital Diseases
Nanjing, Jiangsu, China
View Trial Details